New Parkinson’s Drug Approved in the US: What Does It Do Differently?

AbbVie wins FDA nod for Parkinson's pill

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. This newsletter was composed from a pediatric emergency department. Hot tip, all: Don’t jump off 6-foot playground equipment. You will scare your mother, and wind up in a cast. The need-to-know this morning Kodiak Sciences said Zenkuda, its experimental vision-sparing treatment for a common cause of age-related blindness, …

New Parkinson’s drug approved in the US: What does it do differently?

The FDA approved a new once-daily Parkinson’s pill in the dopamine agonist class, designed to selectively target receptors studied for decades; in trials, AbbVie’s drug improved movement and daily functioning

AbbVie wins FDA nod for Parkinson’s disease drug

AbbVie’s JUVMO (tavapadon) is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson’s disease.